IPC분류정보
국가/구분 |
United States(US) Patent
등록
|
국제특허분류(IPC7판) |
|
출원번호 |
US-0895013
(2001-06-27)
|
발명자
/ 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
Kelly Bauersfeld Lowry & Kelley, LLP
|
인용정보 |
피인용 횟수 :
25 인용 특허 :
6 |
초록
▼
A water dispensing station includes a source of water a water temperature adjustment system connected to the source of water and adapted to adjust water obtained from the source of water, a temperature sensor positioned to sense water temperature of water in the temperature adjusting system, and a d
A water dispensing station includes a source of water a water temperature adjustment system connected to the source of water and adapted to adjust water obtained from the source of water, a temperature sensor positioned to sense water temperature of water in the temperature adjusting system, and a dispensing system connected to the water temperature adjusting system and adapted to selectively dispense water. A controller has processing and memory means and is connected to the water temperature adjusting system and the temperature sensor. The controller is adapted to receive and store water temperature information from the temperature sensor. The station preferably includes a display screen to display information from the controller and input means for the user to input information to the controller. The station can further include a modem so that the controller can communicate with a remote service center. Preferably, the modem is in communication with the controller via transceivers and the modem automatically receives calls from the remote service center. The controller can automatically alert the remote service center when there is a need for service such as filter replacement, component replacement, or bottled water delivery or can alert the remote service center that the user desires to be contacted by the remote service center. The remote service center can check status of the station and send message to the user such as replacement filters are on the way or bottled water will be delivered on a certain date.
대표청구항
▼
A water dispensing station includes a source of water a water temperature adjustment system connected to the source of water and adapted to adjust water obtained from the source of water, a temperature sensor positioned to sense water temperature of water in the temperature adjusting system, and a d
A water dispensing station includes a source of water a water temperature adjustment system connected to the source of water and adapted to adjust water obtained from the source of water, a temperature sensor positioned to sense water temperature of water in the temperature adjusting system, and a dispensing system connected to the water temperature adjusting system and adapted to selectively dispense water. A controller has processing and memory means and is connected to the water temperature adjusting system and the temperature sensor. The controller is adapted to receive and store water temperature information from the temperature sensor. The station preferably includes a display screen to display information from the controller and input means for the user to input information to the controller. The station can further include a modem so that the controller can communicate with a remote service center. Preferably, the modem is in communication with the controller via transceivers and the modem automatically receives calls from the remote service center. The controller can automatically alert the remote service center when there is a need for service such as filter replacement, component replacement, or bottled water delivery or can alert the remote service center that the user desires to be contacted by the remote service center. The remote service center can check status of the station and send message to the user such as replacement filters are on the way or bottled water will be delivered on a certain date. group consisting of halogen, hydroxyl, amino, alkylamino, arylamino, dialkylamino, diarylamino, cyano, nitro, mercapto, carbamido, carbamoyl, carboxyl, thioureido, thiocyanato, sulfonamido, C1_C6alkyl, C2_C6alkenyl, C1_C6alkoxy, and aryl. 2. The compound of claim 1, wherein Rcis H. 3. The compound of claim 2, wherein R3O is linked to position 5 of pyridyl. 4. The compound of claim 3, wherein R3O is arylalkoxy. 5. The compound of claim 4, wherein both R1and R2are H. 6. The compound of claim 5, wherein one of Raand Rbis aryl or thienyl, furyl, pyridinyl, indolyl or 2-oxo-indolyl, and the other of Raand Rbis H. 7. The compound of claim 6, wherein R3O is benzyloxy. 8. The compound of claim 1, wherein R3O is arylalkoxy. 9. The compound of claim 1, wherein both R1and R2are H. 10. The compound of claim 9, wherein Rcis H. 11. The compound of claim 1, wherein one of Raand Rbis aryl or thienyl, furyl, pyridinyl, indolyl or 2-oxo-indolyl, and the other of Raand Rbis H. 12. The compound of claim 11, wherein Rcis H. 13. The compound of claim 12, wherein R3O is arylalkoxy linked to position 5 of pyridyl. 14. The compound of claim 1, wherein the compound is wherein Bn is benzyl. 15. The compound of claim 14, wherein the compound is 16. The compound of claim 14, wherein the compound is 17. A method for treating tumor, comprising administering to a subject in need thereof an effective amount of the compound having the formula: wherein A is C(RaRb); Z is R3O--(Ar)--B, in which B is C(Rc); Ar is pyridyl linked to B at position 2; and R3is H, alkyl substituted with aryl, or aryl; in which aryl is unsubstituted or substituted with one or more substitutents selected from the group consisting of halogen, hydroxyl, amino, alkylamino, arylamino, dialkylamino, diarylamino, cyano, nitro, mercapto, carbamido, carbamoyl, carboxyl, thioureido, thiocyanato, sulfonamido, C1_C6alkyl, C2_C6alkenyl, C1_C6alkoxy, and aryl; each of R1and R2,independently, is H, or C(O)Rd; and one of Raand Rbis thienyl, furyl, pyridinyl, indolyl, 2-oxo-indolyl, aryl, alkyl, or alkyl substituted with aryl, and each of the other of Raand Rb,and Rc,and Rd,independently, is H, alkyl, or aryl; in which alkyl and aryl are unsubstituted or substituted with one or more substitutents selected from the group consisting of halogen, hydroxyl, amino, alkylamino, arylamino, dialkylamino, diarylamino, cyano, nitro, mercapto, carbamido, carbamoyl, carboxyl, thioureido, thiocyanato, sulfonamido, C1_-C6alkyl, C2_C6alkenyl, C1_-C6alkoxy, and aryl. 18. The method of claim 17, wherein the pyridyl is substituted with arylalkoxy at position 5. 19. The method of claim 17, wherein both R1and R2are H. 20. The method of claim 17, wherein one of Raand Rbis aryl or thienyl, furyl, pyridinyl, indolyl or 2-oxo-indolyl, and the other of Raand Rbis H. 21. The method of claim 17, wherein the compound is 22. The method of claim 21, wherein the compound is 23. The method of claim 21, wherein the compound is platelets a JAK-3 inhibitor. 3. A method for selectively inhibiting thrombin-induced platelet aggregation comprising administering to said platelets a JAK-3 inhibitor represented by formula I: wherein: X is selected from the group consisting of HN, R11N, S, O, CH2,and R11CH; R11is (C1-C4)alkyl or (C1-C4)alkanoyl; R1-R5are each independently selected from the group consisting of hydrogen, hydroxy, and halo where at least one of R1-R5is hydroxy; R6,R7,and R8are each independently selected from the group consisting of hydrogen, hydroxy, mercapto, amino, nitro, (C1-C4)alkyl, (C1-C4)alkoxy, (C1-C4)alkylthio, and halo; and R9and R10are each independently selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4)alkoxy, halo, and (C1-C4)alkanoyl; or R9and R10together are methylenedioxy; or a pharmaceutically acceptable salt thereof. 4. The method of claim 3, wherein X is HN. 5. The method of claim 3, wherein the JAK-3 inhibitor is 94'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline; 4-(3'5'-dibromo-4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline; 4-(3'bromo-4'-hydroxyphenyl)-amino-6,7-dimethoxy-quinazoline; or 4-(3'hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. 6. The method of claim 3, wherein the JAK-3 inhibitor is 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline. 7. The method of claim 1 wherein the condition characterized by platelet aggregation comprises embolus formation, thrombolytic complications, disseminated intravascular comgelopathy, thrombosis, coronary heart disease, thromboembolic complications, myocardial infarction, restenosis, or atrial in atrial fibrillation.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.